和誉：ABSK043联合伏美替尼治疗NSCLC的II期临床初步结果良好

Core Viewpoint - The company announced preliminary results from a Phase II clinical study of its oral small molecule PD-L1 inhibitor ABSK043 in combination with the third-generation EGFR-TKI, furmonertinib, for the treatment of non-small cell lung cancer (NSCLC) [1] Group 1: Clinical Study Results - The initial results from the dose escalation phase of the ABSK043-202 study indicate that the "targeted immune combination" regimen shows good safety and tolerability [1] - Regulatory authorities have agreed to expand the study to include first-line treatment research for EGFR mutation-positive and PD-L1 positive NSCLC patients based on the favorable safety profile of the regimen [1]